Safety of stimulant treatment in attention deficit hyperactivity disorder: Part i

Expert Opinion on Drug Safety

Volumn 8, Issue 6, 2009, Pages 655-668

  Merkel Jr , Richard Lawrence ^a   Kuchibhatla, Ajay ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Adverse events; Amphetamine; Attention deficit hyperactivity disorder; Dexmethylphenidate; Dextroamphetamine; Lisdexamfetamine dimesylate; Methylphenidate; Mixed amphetamine salts; Psychostimulants; Substance abuse and dependence

Indexed keywords

ALCOHOL; AMFEBUTAMONE; AMPHETAMINE; ATOMOXETINE; BIPHENTIN; COCAINE; DATRANA; DEXAMPHETAMINE; DEXMETHYLPHENIDATE; FOCALIN ER; ILLICIT DRUG; IMIPRAMINE; LISDEXAMFETAMINE; LONG ACTING DRUG; METHYLPHENIDATE; NICOTINE; PEMOLINE; PLACEBO; PSYCHOSTIMULANT AGENT; PSYCHOTROPIC AGENT; RECREATIONAL DRUG; SHORT ACTING DRUG; UNCLASSIFIED DRUG;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ABNORMAL BEHAVIOR; ABNORMAL DREAMING; AGGRESSION; AGITATION; ALCOHOL CONSUMPTION; ANOREXIA; ANXIETY; ANXIETY DISORDER; ATTENTION DEFICIT DISORDER; AUTISM; BIPOLAR DISORDER; BLOOD PRESSURE; CIGARETTE SMOKING; CLINICAL TRIAL; COLLEGE STUDENT; COMORBIDITY; CONDUCT DISORDER; CRYING; DAY DREAMING; DECREASED APPETITE; DEPRESSION; DIZZINESS; DOSE RESPONSE; DROWSINESS; DRUG ABUSE; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; EUPHORIA; GASTROINTESTINAL SYMPTOM; HABIT; HALLUCINATION; HEALTH SURVEY; HEART PALPITATION; HEART RATE; HIGH SCHOOL STUDENT; HUMAN; HYPERTENSION; INSOMNIA; INTERNET; IRRITABILITY; LOW DRUG DOSE; MAINTENANCE THERAPY; MEDICAL LITERATURE; MEDLINE; MENTAL DEFICIENCY; MENTAL INSTABILITY; MUCOSAL DRYNESS; NAUSEA; NERVOUSNESS; NIGHTMARE; OPPOSITIONAL DEFIANT DISORDER; PSYCHOSIS; PULSE RATE; RACE DIFFERENCE; REVIEW; RISK; RISK FACTOR; SCHIZOPHRENIA; SEX RATIO; SIDE EFFECT; SLEEP DISORDER; STOMACH PAIN; SUBSTANCE ABUSE; SUDDEN DEATH; TACHYCARDIA; TIC; TOBACCO DEPENDENCE; UNSPECIFIED SIDE EFFECT; UPPER ABDOMINAL PAIN; VITAL SIGN; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

ADOLESCENT; ADULT; AMPHETAMINE; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHEMISTRY, PHARMACEUTICAL; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; COMORBIDITY; HUMANS; METHYLPHENIDATE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK; SUBSTANCE-RELATED DISORDERS; YOUNG ADULT;

EID: 70449477071     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740330903279956     Document Type: Review

References (86)

1. Weisler RH. Review of long-acting stimulants in the treatment of attention deficit hyperactivity disorder. Expert Opin Pharmacother 2007;8(6):745-758
2. Barkley RA. Major life activity and health outcomes associated with attention-deficit/ hyperactivity disorder. J Clin Psychiatry 2002;3(Suppl 12):10-15
3. Wolraich ML, McGuinn L, Doffing M. Treatment of attention deficit hyperactivity disorder in children and adolescents: safety considerations. Drug Saf 2007;30(1):17-26
4. Vitiello B. Long-term effects of stimulant medications on the brain: Possible relevance to the treatment of attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 2001;11(1):25-34
5. Barkley RA, McMurray M, Edelbrock CS, Robbins K. Side effects of methylphenidate in children with attention deficit hyperactivity disorder: A systematic, placebo-controlled evaluation. Pediatrics 1990;86:184-192
6. Graham J, Coghill D. Adverse effects of pharmacotherapies for attention-deficit hyperactivity disorder. CNS Drugs 1990;22(3):213-237
7. Wigal T, GreenhillL, Chuang S, et al. Safety and tolerability of methylphenidate in preschool children with ADHD. J Am Acad Child Adolesc Psychiatry 2006;45(11):1294-1303
8. Wolraich ML, Doffing MA. Pharmokinetic considerations in the treatment of attention-deficit hyperactivity disorder with methylphenidate. CNS Drugs 2004;18(4):243-250
9. Lerner M, Wigal T. Long-term safety of stimulant medications used to treat children with ADHD. Pediatr Ann 2008;37(1):37-45
10. Ahmann PA, Waltonen SJ, Olson KA, et al. Placebo-controlled evaluation of ritalin side effects. Pediatrics 1993;86:184-192
11. MTA Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 1999;56:1073-1086
12. Molina BSG, Flory K, Hinshaw SP, et al. Delinquent behavior and emerging substance use in the MTA at 36 months: Prevalence, course, and treatment effects. J Am Acad Child Adolesc Psychiatry 2007;46(8):1028-1040
13. MTA Group. National Institute of Mental Health Multimodal Treatment Study of ADHD Follow-up: changes in effectiveness and growth after the end of treatment. Pediatrics 2004;113:762-769
14. Schachter HM, Pham B, King J, et al. How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis. CMAJ 2001;165(11):1475-1488
15. Arnold LE, Lindsay RL, Conners CK, et al. A double-blind, placebo-controlled withdrawal trial of dexmethylphenidate hydrochloride in children with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 2004;4(4):542-554
16. Biederman J, Quinn D, Weiss M, et al. Efficacy and safety of Ritalin LA-, a new, once daily, extended-release dosage form of methylphenidate, in children with attention deficit hyperactivity disorder. Pediatr Drugs 2003;5(12):833-841
17. Jain U, Hechtman L, Weiss M, et al. Efficacy of a novel biphasic controlled-release methylphenidate formula in adults with attention-deficit/ hyperactivity disorder: Results of a double-blind, placebo-controlled crossover study. J Clin Psychiatry 2007;68(2):268-277
18. Stein MA, Sarampote CS, Waldman ID, et al. A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics 2003;112(5):404-413
19. Biederman J, Mick E, Surman C, et al. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 2005;59:829-835
20. Reimherr FW, Williams ED, Strong RE, et al. A double-blind, placebo-controlled, crossover study of osmotic release oral system methylphenidate in adults with ADHD with assessment of oppositional and emotional dimensions of the disorder. J Clin Psychiatry 2007;68(1):93-101
21. Medori R, Ramos-Quiroga JA, Casas M, et al. A randomized, placebo-controlled trial of three fixed dosage of prolonged-release OROS methylphenidate in adults with attention-deficit/ hyperactivity disorder. Biol Psychiatry 2008;63(10):981-989
22. McGough JJ, Wigal SB, Abikoff H, et al. A randomized, double-blind, placebo controlled, laboratory classroom assessment of methylphenidate transdermal system in children with ADHD. J Atten Disord 2006;9(3):476-485
23. Greenhill LL, Muniz R, Ball RR, et al. Efficacy and safety of dexmethylphenidate extended-release capsules in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2006;45(7):817-823 (Pubitemid 43932908)
24. Spencer TJ, Adler LA, McGough JJ, et al. Efficacy and safety of dexemethylphenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 2007;61:1380-1387
25. Greenhill LL, Findling RL, Swanson JM, for the ADHD study group. A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/ hyperactivity disorder. Pediatrics 2002;109:e39
26. Stein MA, Blondis TA, Schnitzler ER, et al. Methylphenidate dosing: Twice daily versus three times daily. Pediatrics 1996;98:748-756
27. Wilens TE, McBurnett K, Stein M, et al. ADHD treatment with once-daily OROS methylphenidate: final results from a long-term open-label study. Arch Gen Psychiatry 2005;44:1015-1020
28. Biederman J, Lopez FA, Boellner SW, Chandler MC. A randomized, double-blind, placebo-controlled, parallel group study of SLI381 (Adderall XR) in children with attention-deficit/ hyperactivity disorder. Pediatrics 2002;110:258-266
29. Weisler RH, Biederman J, Spencer TJ, et al. Mixed amphetamine salts extended-release in the treatment of adult ADHD: A randomized, controlled trial. CNS Spectr 2006;11:625-639
30. Biederman J, Krishnan S, Zhang Y, et al. Efficacy and tolerability of lisdexamfetamine dimesylate (NPR-104) in children with attention-deficit/ hyperactivity disorder: A phase III, multicenter, randomized, double-blind, forced dose, parallel-group study. Clin Ther 2007;29:450-463
31. McGough JJ, Biederman J, Wigal SB, et al. Long-term tolerability and effectiveness of once-daily mixed amphetamine salts (Adderall XR) in children with ADHD. Pediatrics 2005;147:348-354
32. Wigal S, Swanson JM, Feifel D, et al. A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d, l-threo-methylphenidate hydrochloride in children with attention-deficit/ hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2004;43(11):1406-1414
33. Weiss M, Wasdell M, Patin J. A post hoc analysis of d-threo- methylphenidate hydrochloride (focalin) versus d,l-threo-methylphenidate hydrochloride (ritalin). J Am Acad Child Adolesc Psychiatry 2004;43(11):1415- 1421
34. Wolraich ML, Greenhill LL, Pelham W, et al. Randomized, controlled trial of OROS methylphenidate once a day in children with attention-deficit/ hyperactivity disorder. Pediatrics 2001;108(4):883-892
35. Findling RL, Bukstein OG, Melmed RD, et al. A randomized, double-blind, placebo-controlled, parallel-group study of methylphenidate transdermal system in pediatric patients with attention-deficit/ hyperactivity disorder. J Clin Psychiatry 2008;69(1):149-159
36. Swanson JM, Wigal SB, Wigal T, et al. A comparison of once-day extended release methylphenidate formulations in children with attention-deficit/ hyperactivity disorder in the laboratory school (The Comacs Study). Pediatrics 2004;113:206-216
37. Biederman J, Boellner SW, Childress A, et al. Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: A double-blind, placebo-controlled, crossover analog classroom study. Biol Psychiatry 2007;62:970-976
38. Conners CK. Psychological effects of stimulant drugs in children with minimal brain dysfunction. Pediatrics 1972;49(5):702-708
39. Winsberg BG, Press M, Bialer I, Jupietz S. Dextroamphetamine and methylphenidate in the treatment of hyperactive/aggressive children. Pediatrics 1974;53(2):236-241
40. Pelham WE, Greenslade KE, Vodde-Hamilton M, et al. Relative efficacy of long-acting stimulants on children with attention-deficit hyperactivity disorder: A comparison of standard methylphenidate, sustained-release methylphenidate, sustained-release dextroamphetamine, and pemoline. Pediatrics 1990;86(2):226-237
41. Arnold LE, Christopher J, Huestes RD, Smeltzer DJ. Methylphenidate vs. dextroamphetamine vs caffeine in minimal brain dysfunction: controlled comparison by placebo washout design with bayes' analysis. Arch Gen Psychiatry 1978;35(4):463-473
42. Elia J, Borcherding BG, Rappoport JL, Keysor CS. Methylphenidate and dextroamphetamine treatments of hyperactivity: Are there true nonresponders? Psychiatry Res 1991;36:141-155
43. Efron D, Jarman FC, Barker MJ. Side effects of methylphenidate and dextroamphetamine in children with attention deficit hyperactivity disorder: A double-blind, crossover trial. Pediatrics 1997;100:662-666
44. Pelham WE, Gnagy EM, Chronis AM, et al. A comparison of morning-only and morning/late afternoon adderall to morning-only, twice-daily, and three times-daily methylphenidate in children with attention-deficit/ hyperactivity disorder. Pediatrics 1999;104(6):1300-1311
45. Pelham WE, Aronoff HR, Midlam JK, et al. A comaprison of ritalin and adderall: Efficacy and time-course in children with attention-deficit/ hyperactivity disorder. Pediatrics 1999;103(4):43-57
46. Swanson J, Wigal S, Greenhill L, et al. Analog classroom assessment of adderall in children with ADHD. J Am Acad Child Adolesc Psychiatry 1998;37(5):519-526
47. Pliszka SR, Browne RG, Overa RL, Wynne SK. A double-blind, placebo-controlled study of adderall and methylphenidate in the treatment of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2000;39(5):619-626
48. Manos MJ, Short EJ, Finding RL. Differential effectiveness of methylphenidate and adderall in school-age youths with attention-deficit/ hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1999;38(7):813-819
49. Peterson K, McDonagh MS, Fu R. Comparative benefits and harms of competing medications for adults with attention-deficit hyperactivity disorder: A systematic review and indirect comparison meta-analysis,. Psychopharmacology 2008;197:1-11
50. Musten LM, Firestone P, Pisterman S, et al. Effects of methylphenidate onpreschool children with ADHD: cognitive and behavioral functions. J Am Acad Child Adolesc Psychiatry 1997;35:1407-1415
51. Ghuman JK, Ginsburg GS, Subramaniam G, et al. Psychostimulants in preschool children with attention-deficit/ hyperactivity disorder: clinical evidence from a developmental disorders institution. J Am Acad Child Adolesc Psychiatry 2001;40:516-524
52. Handen BL, Feldman HM, Lurier A, Murray PJ. Efficacy of methylphenidate among preschool children with developmental disabilities and ADHD. J Am Acad Child Adolesc Psychiatry 1999;38:805-812
53. Findling RL, Short EJ, Manos JM. Developmental aspects of psychostimulant treatment in children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiary 2001;40(12):1441-1447
54. Gittelman R, Mannuzza S, Shenker R, Bonagura N. Hyperactive boys almost grown up. I. Psychiatric status. Arch Gen Psychiatry 1985;42(10):937-947
55. Smith BH, Waschbusch DA, Willoughby MT, Evans S. The efficacy, safety, and practicality of treatments for adolescents with attention-deficit/ hyperactivity disorder. Clin Child Fam Psychol Rev 2000;3(4):243-267
56. Smith BH, Pelham WE, Evans S, et al. Dosage effects of methylphenidate on the social behavior of adolescents diagnosed with attention-deficit hyperactivity disorder. Exp Clin Psychopharmacol 1998;6(2):187-204
57. Goodman DW, Ginsberg L, Weisler RH, et al. An interim analysis of the quality of life, effectiveness, safety, and tolerability (QUEST) evaluation of mixed amphetamine salts extended release in adults with ADHD. CNS Spectr 2005;10(12 Suppl 20):26-34
58. Ashton H, Gallagher P, Moore, B. The adult psychiatrist's dilemma: Psychostimulant use in attention deficit/ hyperactivity disorder. J Psychopharm 2006;20(5):602-610
59. Hechtman L, Weiss G, Perlman T, et al. Young adult outcome of hyperactive children who received long-term stimulant treatment. J Am Acad Child Adolesc Psychiatry 1984;23:261-269
60. Feldman H, Crumrine P, Handen BL. Methylphenidate in children with seizures and attention-deficit disorder. Am J Dis Child 1989;143:1081-1086
61. Handen BL, Feldman H, Gosling A, et al. Adverse side effects of methylphenidate among mentally retarded children with ADHD. J Am Acad Child Adolesc Psychiatry 1991;30:241-245
62. Pearson DA, Santos CW, Roache JD, et al. Treatment effects of methylphenidate on behavioral adjustment in children with mental retardation and ADHD. J Am Acad Child Adolesc Psychiatry 2003;42(2):209-216
63. Handen BL, Johnson CR, Lubetsky M. Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. J Autism Dev Disord 2000;30(3):245-255
64. Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorder with hyperactivity. Arch Gen Psychiatry 2005;62:1266-1274
65. Kolko DJ, Bukstein OG, Barron J. Methylphenidate and behavior modification in children with ADHD and comorbid ODD or CD: main and incremental effects across settings. J Am Acad Child Adolesc Psychiatry 1999;38(5):578-586
66. Jensen PS, Hinshaw SP, Swanson JM, et al. Findings from the NIMH Multimodal Treatment Study of ADHD (MTA): Implications and applications for primary care providers, developmental and behavioral. Pediatrics 2001;22(1):60-73
67. DuPont RL, Coleman JJ, Bucher RH, Wilford BB. Characteristics and motives of college students who engage in nonmedical use of methylphenidate. Am J Addict 2008;17:167-171
68. McCabe SE, West BT, Wechler H. Trends and college-level characteristics associated with the non-medical use of prescription drugs among US college students from 1993 to 2001. Addiction 2007;102:455-465
69. Teter CJ, McCabe SE, LaGrange K, et al. Illicit use of specific prescription stimulants among college students: Prevalence, motives, and routes of administration. Pharmacotherapy 2006;26(10):1501-1510
70. McCabe SE.Misperceptions of non-medical prescription drug use: A web survey of college students. Addict Behav 2008;33:713-724
71. Upadhyaya HP, Rose K, Wang W, et al. Attention deficit hyperactivity disorder, medication treatment and substance use patterns among adolescents and young adults. J Child Adolesc Psychopharmacol 2005;15:799-809
72. Wilens TE, Gignac M, Swezey A, et al. Characteristics of adolescents and young adults with ADHD who divert of misuse their prescribed medications. J Am Acad Child Adolesc Psychiatry 2006;45(4):408-414
73. Teter CJ, McCabe SE, Cranford JA, et al. Prevalence and motives for illicit use of prescription stimulants in an undergraduate student sample. J Am Coll Health 2005;53(6):253-262
74. McCabe SE, Teter CJ, Boyd CJ. Medical use, illicit use, and diversion of abusable prescription drugs. J Am ColL Health 2006;54(5):269-278
75. McCabe SE, Teter CJ, Boyd CJ, Guthrie SK. Prevalence and correlated of illicit Methylphenidate use among 8th, 10th, and 12th grade students in the United States 2001. J Adolesc Health 2004;35:501-504
76. Boyd CJ, McCabe SE, Cranford JA, Young A. Prescription drug abuse and diversion among adolescents in a Southeast Michigan School District. Arch Pediatr Adolesc Med 2007;161:276-281
77. Wilens TE, Adler LA, Adams J, et al. Misuse and diversion of stimulants prescribed for ADHD: A sysematic review of the literature. J Am Acad Child Adolesc Psychiatry 2008;7(1):21-31
78. Wilens TE. Attention deficit hyperactivity disorder and substance use disorders. Am J Psychiatry 2006;163(12):2059-2063
79. Faraone SV, Wilens TE. Effect of stimulant medications for attention-deficit/ hyperactivity disorder on later substance use and the potential for stimulant misuse, abuse, and diversion. J Clin Psychiatry 2007;68(Suppl 11):15-22
80. Hechtman L. Long-term treatment of children and adolescents with attention-deficit/hyperactivity disorder (ADHD). Curr Psychiatry Rep 2006;8:398-408
81. Wilens TE, Faraone SV, Biederman J, Gunawardene S. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature Pediatrics 2003;11:179-185
82. Biederman J, Monuteaux MC, Spencer T, et al. Stimulant therapy and risk for subsequent substance use disorders in male adults with ADHD: A naturalistic controlled 10-year follow-up study. AJP 2008;165:597-603
83. Schubiner H, Saules KK, Arfken CL, et al. Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Exp Clin Psychopharmacol 2002;10(3):286-294
84. Upadhyaya HP. Managing attention-deficit/hyperactivity disorder in the presence of substance use disorder. J Clin Psychiatry 2007;68(Suppl 11):23-30
85. Firestone P, Musten LM, Pisterman S, et al. Short-term side effects of stimulant medication are increased in preschool children with attention-deficit/ hyperactivity disorder: A double-blind placebo-controlled study. J Child Adolesc Psychopharmacol 1998;8:13-25
86. Jensen PS, Arnold E, Swanson JM, et al. 3-Year followup of the NIMH MTA study. J Am Acad Child Adolesc Psychiatry 2007;46(8):989-1002